Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | CPB1 | P15086 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25453638 | 0.90 | CA1 (0.61) | HTTFOLH1MMP2MMP9TGM2 | |
| SCHEMBL25455599 | 0.87 | HTT (0.60) | HTTFOLH1LMNASMN1; SMN2MMP2 | |
| SCHEMBL9810168 | 0.85 | FOLH1 (0.53) | HTTFOLH1LMNASMN1; SMN2MMP2 | |
| SCHEMBL9810164 | 0.85 | FOLH1 (0.53) | HTTFOLH1LMNASMN1; SMN2MMP2 | |
| SCHEMBL10032568 | 0.84 | HTT (0.67) | HTTFOLH1LMNASMN1; SMN2TGM2 | |
| Ammonia Solution, Strong SCHEMBL8060380 | 0.83 | HTT (0.65) | HTTFOLH1LMNASMN1; SMN2TGM2 | |
| SCHEMBL30689097 | 0.82 | FOLH1 (0.64) | HTTFOLH1LMNASMN1; SMN2MMP2 | |
| SCHEMBL17995299 | 0.82 | FOLH1 (0.64) | HTTFOLH1LMNASMN1; SMN2MMP2 | |
| SCHEMBL7390273 | 0.82 | FOLH1 (0.58) | HTTFOLH1MMP2MMP9TGM2 | |
| SCHEMBL8437001 | 0.82 | HTT (0.63) | HTTFOLH1LMNASMN1; SMN2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | NATIONAL INSTITUTES OF HEALTH | 2023-05-11 | — | — | US | disclosed |
| WO-2021202600-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143470-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | HAVCR2, CD44, ENGASE | HTT 1336/4885FOLH1 2246/4885LMNA 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.